-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

Benzinga·04/22/2026 11:59:22
Listen to the news
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $15 price target.